Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roche has come under pressure to improve its pipeline with medicines it can commercialize soon as a windfall of revenue from products used in the COVID-19 pandemic comes to an end.
Roche Holding AG will pay $7.1 billion to acquire Telavant Holdings Inc., a developer of a promising therapy for treating inflammatory bowel disease, in a bid to shore up its pipeline of experimental medicines.
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for ...
Pfizer’s curious offloading of a drug that was quickly sold to a rival